Follow last change Aug 2026 re-read 3 minutes ago

AG10

also known as acoramidis · Eidos Therapeutics AG10

targets TTR

Developed for: amyloidosis · familial amyloid neuropathy · familial cardiomyopathy · wild type ATTR amyloidosis
Investigated by: Eidos Therapeutics, a BridgeBio company · Celerion

Trials 3

today NCT04418024 · Ph 3 NCT03536767 · Ph 2 NCT03294707 · Ph 1

2018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 11 trial
Phase 1	NCT03294707	Sep 2017 → Feb 2018	—	Eidos Therapeutics, a BridgeBio company	Completed	No outcome recorded
Phase 21 trial · 1 met primary
Phase 2	NCT03536767	Aug 2018 → Jul 2027 expected	amyloidosis	Eidos Therapeutics, a BridgeBio company	Active not recruiting	Met primary
Phase 31 trial
Phase 3	NCT04418024	Oct 2020 → Mar 2024	familial amyloid neuropathy	Eidos Therapeutics, a BridgeBio company	Withdrawn	No outcome recorded
Comparator or background therapy1 trial
Phase 2	NCT03458130 Comparator	Apr → Oct 2018	familial cardiomyopathy, wild type ATTR amyloidosis	Eidos Therapeutics, a BridgeBio company	Completed	No outcome recorded

Press releases naming this drug 49 releases

Date	Issuer	Release
2026-08-30	Eidos Therapeutics, a BridgeBio company	Acoramidis Demonstrates Reversal of Cardiac Structural Disease Progression and Functional Decline and Significantly Increases Days Alive and Free from Hospitalization in ATTR-CM bridgebio.com ↗
2026-08-26	Eidos Therapeutics, a BridgeBio company	BridgeBio Announces First Participant Dosed in ASCEND-ATTR, a Phase 3b/4 Study Evaluating the Long-Term Effects of Acoramidis on Disease Regression in ATTR-CM bridgebio.com ↗
2026-08-24	Eidos Therapeutics, a BridgeBio company	BridgeBio to Present New Acoramidis Data from Open-Label Extension Analyses in ATTR-CM at ESC Congress 2026 bridgebio.com ↗
2026-07-02	Eidos Therapeutics, a BridgeBio company	Acoramidis Associated with First-Ever Early and Sustained Direct Kidney-Protective Effects in ATTR-CM bridgebio.com ↗
2026-05-11	Eidos Therapeutics, a BridgeBio company	Acoramidis Continues to Demonstrate Disease-Modifying Effects in ATTR-CM, Reducing sTTR Variability and Outpatient Worsening Heart Failure bridgebio.com ↗
2026-05-06	Eidos Therapeutics, a BridgeBio company	BEYONTTRA™ (acoramidis), the First Near-Complete TTR Stabilizer (≥90%), Approved by ANVISA to Treat ATTR-CM in Brazil bridgebio.com ↗
2026-05-04	Eidos Therapeutics, a BridgeBio company	BridgeBio to Present New Acoramidis Data on Disease Progression, Biomarkers, and Clinical Outcomes at ESC-Heart Failure 2026 bridgebio.com ↗
2026-03-30	Eidos Therapeutics, a BridgeBio company	Acoramidis Significantly Reduces the Risk of All-Cause and Cardiovascular Mortality in Patients with ATTR-CM through Month 54 bridgebio.com ↗
2025-11-08	Eidos Therapeutics, a BridgeBio company	Acoramidis Significantly Reduces All-cause Mortality in the Overall ATTR-CM Variant and V142I (V122I) Populations bridgebio.com ↗
2025-09-28	Eidos Therapeutics, a BridgeBio company	Acoramidis Begins to Reduce Cumulative Cardiovascular Outcomes Within the First Month of Treatment in Patients with ATTR-CM bridgebio.com ↗
2025-08-30	Eidos Therapeutics, a BridgeBio company	Acoramidis Demonstrates Statistically Significant Reduction in Cardiovascular Mortality (CVM) through Month 42 of the ATTRibute-CM Open Label Extension bridgebio.com ↗
2025-05-20	Eidos Therapeutics, a BridgeBio company	Acoramidis Reduced Incidence of Atrial Fibrillation Events in Patients with ATTR-CM bridgebio.com ↗
2025-05-19	Eidos Therapeutics, a BridgeBio company	Early and Sustained Increase in Serum TTR Levels by Acoramidis Independently Predicted Improved Survival in the ATTRibute-CM Study bridgebio.com ↗
2025-05-13	Eidos Therapeutics, a BridgeBio company	First Participant Dosed with Acoramidis in ACT-EARLY, the First Ever ATTR Primary Prevention Study bridgebio.com ↗
2025-04-28	Eidos Therapeutics, a BridgeBio company	BEYONTTRA® (acoramidis), the First Near-complete TTR Stabilizer (≥90%), Approved by the UK Medicines and Healthcare Products Regulatory Agency to Treat ATTR-CM bridgebio.com ↗
2025-03-31	Eidos Therapeutics, a BridgeBio company	acoramidis shows statistically significant improvements in cardiovascular outcomes in patients with variant attr-cm bridgebio.com ↗
2025-03-27	Eidos Therapeutics, a BridgeBio company	beyonttra™ (acoramidis), the first near-complete ttr stabilizer (≥90%), approved in japan to treat attr-cm bridgebio.com ↗
2025-02-11	Eidos Therapeutics, a BridgeBio company	beyonttra™ (acoramidis), the first near complete ttr stabilizer (≥90%), approved by the european commission to treat attr-cm bridgebio.com ↗
2024-12-13	Bayer	Acoramidis receives positive CHMP opinion for treatment of transthyretin amyloid cardiomyopathy bayer.com ↗
2024-12-13	Eidos Therapeutics, a BridgeBio company	acoramidis receives positive chmp opinion for treatment of transthyretin amyloid cardiomyopathy (attr-cm) bridgebio.com ↗
2024-11-22	Eidos Therapeutics, a BridgeBio company	attruby™ (acoramidis), a near complete ttr stabilizer (≥90%), approved by fda to reduce cardiovascular death and cardiovascular-related hospitalization in attr-cm patients bridgebio.com ↗
2024-11-18	Eidos Therapeutics, a BridgeBio company	open-label extension data confirms sustained benefit of acoramidis on cardiovascular outcomes, including statistically significant reduction in acm within 36 months bridgebio.com ↗
2024-10-03	Eidos Therapeutics, a BridgeBio company	bridgebio to present outcomes data through 42 months from the open-label extension of attribute-cm, the phase 3 study of acoramidis for treatment of attr-cm, at 2024 aha scientific sessions bridgebio.com ↗
2024-09-27	Eidos Therapeutics, a BridgeBio company	bridgebio shares recurrent event analysis of attribute-cm, demonstrating a 42% reduction by acoramidis on the composite endpoint of all-cause mortality and recurrent cardiovascular-related hospitalization events bridgebio.com ↗
2024-08-30	Eidos Therapeutics, a BridgeBio company	bridgebio shares data on serum ttr increase when switching participants from placebo and tafamidis to acoramidis in attribute-cm and its open-label extension bridgebio.com ↗
2024-08-29	Eidos Therapeutics, a BridgeBio company	bridgebio to present additional analyses from the phase 3 attribute-cm trial of acoramidis in patients with transthyretin amyloid cardiomyopathy (attr-cm) at the esc congress 2024 and the hfsa annual meeting 2024 bridgebio.com ↗
2024-05-29	Eidos Therapeutics, a BridgeBio company	additional data showing acoramidis increases serum transthyretin which is associated with improved cardiovascular outcomes presented at isa from bridgebio pharma’s phase 3 attribute-cm study in transthyretin amyloid cardiomyopathy (attr-cm) bridgebio.com ↗
2024-05-24	Eidos Therapeutics, a BridgeBio company	bridgebio pharma to present additional analyses from the phase 3 attribute-cm study of acoramidis in patients with transthyretin amyloid cardiomyopathy (attr-cm) at the 2024 isa meeting bridgebio.com ↗
2024-05-13	Eidos Therapeutics, a BridgeBio company	bridgebio pharma presents additional data and analyses from its phase 3 attribute-cm study in transthyretin amyloid cardiomyopathy (attr-cm) at esc-hf, including that acoramidis treatment significantly reduced all-cause mortality in a pre-specified sensitivity analysis of the entire study population bridgebio.com ↗
2024-03-04	Eidos Therapeutics, a BridgeBio company	bridgebio pharma and bayer announce european licensing agreement for acoramidis in attr-cm bridgebio.com ↗
2024-02-05	Eidos Therapeutics, a BridgeBio company	bridgebio pharma announces u.s. food and drug administration (fda) acceptance of new drug application (nda) for acoramidis for the treatment of patients with transthyretin amyloid cardiomyopathy (attr-cm) bridgebio.com ↗
2024-02-02	Eidos Therapeutics, a BridgeBio company	bridgebio pharma shares positive results of single-arm phase 3 study of acoramidis in japanese patients with transthyretin amyloid cardiomyopathy (attr-cm) including no mortality reported in the trial at 30 months bridgebio.com ↗
2024-01-10	Eidos Therapeutics, a BridgeBio company	bridgebio pharma announces publication of positive results from phase 3 attribute-cm study of acoramidis for patients with transthyretin amyloid cardiomyopathy (attr-cm) in the new england journal of medicine bridgebio.com ↗
2023-12-05	Eidos Therapeutics, a BridgeBio company	bridgebio pharma announces submission of new drug application (nda) to u.s. food and drug administration (fda) for acoramidis for the treatment of patients with transthyretin amyloid cardiomyopathy (attr-cm) bridgebio.com ↗
2023-11-12	Eidos Therapeutics, a BridgeBio company	bridgebio pharma presents additional clinical outcomes data from the phase 3 attribute-cm study of acoramidis in patients with transthyretin amyloidosis cardiomyopathy (attr-cm) bridgebio.com ↗
2023-08-27	Eidos Therapeutics, a BridgeBio company	bridgebio presents detailed positive results from phase 3 attribute-cm study of acoramidis for patients with transthyretin amyloid cardiomyopathy (attr-cm) at european society of cardiology congress 2023 bridgebio.com ↗
2023-07-17	Eidos Therapeutics, a BridgeBio company	bridgebio announces consistently positive results from phase 3 attribute-cm study of acoramidis for patients with transthyretin amyloid cardiomyopathy (attr-cm) bridgebio.com ↗
2022-04-03	Eidos Therapeutics, a BridgeBio company	bridgebio pharma presents updated results from phase 2 open-label extension study of acoramidis in transthyretin amyloid cardiomyopathy (attr-cm) bridgebio.com ↗
2022-03-28	Eidos Therapeutics, a BridgeBio company	bridgebio pharma to present updated results from phase 2 open-label extension study of acoramidis in transthyretin amyloid cardiomyopathy (attr-cm) at the american college of cardiology (acc) annual scientific session & expo bridgebio.com ↗
2019-11-16	Eidos Therapeutics, a BridgeBio company	bridgebio and eidos present data from phase 2 open label extension suggesting long-term tolerability of ag10 and stabilization of transthyretin amyloid cardiomyopathy disease measures bridgebio.com ↗
2019-02-27	Eidos Therapeutics, a BridgeBio company	eidos therapeutics initiates attribute-cm, a phase 3 study of ag10 in attr-cm with registrational 12-month endpoint bridgebio.com ↗
2018-11-10	Eidos Therapeutics, a BridgeBio company	eidos therapeutics announces positive phase 2 data for ag10 in symptomatic patients with mutant or wild-type ttr amyloid cardiomyopathy bridgebio.com ↗
2018-10-26	Eidos Therapeutics, a BridgeBio company	eidos therapeutics receives positive opinion for orphan designation from the european medicines agency for ag10, a potent oral stabilizer for the treatment of transthyretin amyloidosis bridgebio.com ↗
2018-10-05	Eidos Therapeutics, a BridgeBio company	eidos therapeutics to present phase 2 data for ag10 in ttr amyloidosis cardiomyopathy at the aha 2018 scientific sessions in a late-breaking featured science oral presentation bridgebio.com ↗
2018-10-03	Eidos Therapeutics, a BridgeBio company	fda grants orphan drug designation to eidos therapeutics’ product candidate, ag10, for treatment of transthyretin amyloidosis bridgebio.com ↗
2018-09-17	Eidos Therapeutics, a BridgeBio company	eidos therapeutics presents data from its phase 1 clinical trial of ag10 at the 22nd annual scientific meeting of the heart failure society of america bridgebio.com ↗
2018-08-23	Eidos Therapeutics, a BridgeBio company	eidos therapeutics announces publication of ag10 molecular design in journal of medicinal chemistry bridgebio.com ↗
2018-05-03	Eidos Therapeutics, a BridgeBio company	eidos therapeutics initiates phase 2 clinical trial for ag10 targeting transthyretin amyloidosis cardiomyopathy bridgebio.com ↗
2017-09-28	Eidos Therapeutics, a BridgeBio company	eidos therapeutics initiates first clinical study for ag10 targeting transthyretin amyloidosis, appoints camille landis as chief business officer bridgebio.com ↗

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 6 sources stand behind the page.

Field	Value	Cited text
Known as	AG10	ClinicalTrials.gov intervention name — accepted as the source's own label NCT03458130 ↗ 3 NCT04418024 ↗ NCT03294707 ↗ NCT03536767 ↗
Known as	acoramidis	“BACKGROUND: Acoramidis achieves near-complete (≥90%) transthyretin stabilization and is approved to reduce cardiovascular-related hospitalization in transthyretin amyloid...” PMID 42389794 ↗ Jul 2026
Known as	Eidos Therapeutics AG10	“Eidos Therapeutics AG10” NCT03294707 ↗
Route	Oral	“AG10 oral tablet, administered by mouth, once” NCT03294707 ↗
Target	TTR	“AG10 is a selective, oral TTR stabilizer under development for transthyretin amyloidosis cardiomyopathy (ATTR-CM) that mimics a protective TTR mutation.” PMID 30885685 ↗ Mar 2019